Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of H008 injection versus esomeprazole after endoscopic hemostasis for peptic ulcer upper gastrointestinal bleeding
ChiCTR2500103004Phase 3Not yet recruiting
- Sponsor
- Union Hospital
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of keverprazan in Peptic ulcer disease (PUD) and upper gastrointestinal bleeding (UGIB) (2 arms), sponsored by Union Hospital. Primary endpoint: No rebleeding rate within 72 hours after treatment initiation. Planned start May 2025; status: not yet recruiting.
02
Drugs
keverprazan
03
Conditions
Peptic ulcer disease (PUD)upper gastrointestinal bleeding (UGIB)
Beyond the preview
Go deeper on ChiCTR2500103004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103004.